Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Regularly Transfused Thalassemia
NCT02049450Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of ruxolitinib in beta thalassemia major, sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
03
Conditions
beta thalassemia major
Beyond the preview
Go deeper on NCT02049450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049450.